{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:34:07Z","timestamp":1787070847362,"version":"build-2736575974"},"reference-count":50,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health with Ricerca Corrente"},{"name":"5 \u00d7 1000 funds for the IEO European Institute of Oncology IRCCS"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Renal cell carcinoma (RCC) is one of the most frequently diagnosed tumors and a leading cause of death. The high risk of local recurrence and distant metastases represent a significant clinical issue. Different image-guided ablation techniques can be applied for their treatment as an alternative to surgery, radiotherapy or systemic treatments. A retrospective analysis was conducted at our institution, including a total number of 34 RCC patients and 44 recurrent RCC tumors in different locations (kidney, lung, adrenal gland, liver, pancreas, pararenal and other) using microwave ablation, radiofrequency ablation, cryoablation and laser ablation. The estimated time to local and distant tumor progression after treatment were 22.53 \u00b1 5.61 months and 24.23 \u00b1 4.47 months, respectively. Systemic treatment was initiated in 10\/34 (29%) treated patients with a mean time-to-systemic-therapy of 40.92 \u00b1 23.98 months. Primary technical success was achieved in all cases and patients while the primary efficacy rate was achieved in 43\/44 (98%) cases and 33\/34 (97%) patients, respectively, with a secondary technical success and efficacy rate of 100%. At a mean follow-up of 57.52 months \u00b1 27.86 months, local tumor progression occurred in 3\/44 (7%) cases and distant progression in 25\/34 (74%) patients. No significant complications occurred. Image-guided ablations can play a role in helping to better control recurrent disease, avoiding or delaying the administration of systemic therapies and their significant adverse effects.<\/jats:p>","DOI":"10.3390\/jcm12154902","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T02:07:17Z","timestamp":1690423637000},"page":"4902","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Image-Guided Ablations in Patients with Recurrent Renal Cell Carcinoma"],"prefix":"10.3390","volume":"12","author":[{"given":"Gaetano","family":"Aurilio","sequence":"first","affiliation":[{"name":"Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia IEO, European Institute of Oncology IRCCS, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4726-2692","authenticated-orcid":false,"given":"Giovanni","family":"Mauri","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology, Istituto Europeo di Oncologia IEO, European Institute of Oncology IRCCS, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6711-8084","authenticated-orcid":false,"given":"Duccio","family":"Rossi","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology, Istituto Europeo di Oncologia IEO, European Institute of Oncology IRCCS, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8523-9226","authenticated-orcid":false,"given":"Paolo","family":"Della Vigna","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology, Istituto Europeo di Oncologia IEO, European Institute of Oncology IRCCS, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Bonomo","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology, Istituto Europeo di Oncologia IEO, European Institute of Oncology IRCCS, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca Maria","family":"Varano","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology, Istituto Europeo di Oncologia IEO, European Institute of Oncology IRCCS, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Maiettini","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology, Istituto Europeo di Oncologia IEO, European Institute of Oncology IRCCS, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5780-3774","authenticated-orcid":false,"given":"Maria Cossu","family":"Rocca","sequence":"additional","affiliation":[{"name":"Department of Oncology, Istituto Europeo di Oncologia IEO, European Institute of Oncology IRCCS, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Verri","sequence":"additional","affiliation":[{"name":"Department of Oncology, Istituto Europeo di Oncologia IEO, European Institute of Oncology IRCCS, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cullur\u00e0","sequence":"additional","affiliation":[{"name":"Department of Oncology, Istituto Europeo di Oncologia IEO, European Institute of Oncology IRCCS, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Nol\u00e9","sequence":"additional","affiliation":[{"name":"Department of Oncology, Istituto Europeo di Oncologia IEO, European Institute of Oncology IRCCS, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7330-0499","authenticated-orcid":false,"given":"Franco","family":"Orsi","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology, Istituto Europeo di Oncologia IEO, European Institute of Oncology IRCCS, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","article-title":"Renal cancer","volume":"387","author":"Capitanio","year":"2016","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40364-020-00195-3","article-title":"Trends and projections of kidney cancer incidence at the global and national levels, 1990\u20132030: A Bayesian age-period-cohort modeling study","volume":"8","author":"Du","year":"2020","journal-title":"Biomark. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/01.RVI.0000094584.83406.3e","article-title":"Society of Interventional Radiology Clinical Practice Guidelines","volume":"14","author":"Sacks","year":"2003","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1148\/radiol.2021203715","article-title":"Consensus Guidelines for the Definition of Time-to-Event End Points in Image-guided Tumor Ablation: Results of the SIO and DATECAN Initiative","volume":"301","author":"Puijk","year":"2021","journal-title":"Radiology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1097\/01.ju.0000165693.68449.c3","article-title":"Renal cell carcinoma 2005: New frontiers in staging, prognostication and targeted molecular therapy","volume":"173","author":"Lam","year":"2005","journal-title":"J. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: A population-based analysis","volume":"23","author":"Bianchi","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/cncr.25836","article-title":"Survival after complete surgical resection of multiple metastases from renal cell carcinoma","volume":"117","author":"Alt","year":"2011","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/S1470-2045(14)70235-9","article-title":"Local treatments for metastases of renal cell carcinoma: A systematic review","volume":"15","author":"Dabestani","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"17822","DOI":"10.1038\/s41598-021-97365-6","article-title":"The prognosis and clinicopathological features of different distant metastases patterns in renal cell carcinoma: Analysis based on the SEER database","volume":"11","author":"Wei","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/14740338.2020.1811226","article-title":"Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: A systematic review and meta-analysis","volume":"19","author":"Massari","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.euo.2019.09.002","article-title":"First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis","volume":"2","author":"Hahn","year":"2019","journal-title":"Eur. Urol. Oncol."},{"key":"ref_13","unstructured":"Culp, S.H., and Wood, C.G. (2013). Renal Cell Carcinoma, Humana Press."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1464-410X.2009.08484.x","article-title":"Nephrectomy improves survival in patients with invasion of adjacent viscera and absence of nodal metastases (stage T4N0 renal cell carcinoma)","volume":"104","author":"Capitanio","year":"2009","journal-title":"BJU Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ucl.2020.04.012","article-title":"The Evolving Role of Metastasectomy for Patients with Metastatic Renal Cell Carcinoma","volume":"47","author":"Abel","year":"2020","journal-title":"Urol. Clin. N. Am."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/j.clgc.2016.01.012","article-title":"Local Recurrence After Curative Surgical Treatment of Renal Cell Cancer: A Study of 91 Patients","volume":"14","author":"Du","year":"2016","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.juro.2015.02.2943","article-title":"Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy","volume":"194","author":"Thomas","year":"2015","journal-title":"J. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.urology.2021.03.038","article-title":"Local and Regional Recurrences of Clinically Localized Renal Cell Carcinoma after Nephrectomy: A 15 Year Institutional Experience with Prognostic Features and Oncologic Outcomes","volume":"154","author":"Ray","year":"2021","journal-title":"Urology"},{"key":"ref_19","first-page":"1","article-title":"Surveillance strategies for renal cell carcinoma patients following nephrectomy","volume":"8","author":"Chin","year":"2006","journal-title":"Rev. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0002-9610(02)00806-1","article-title":"Cryoablation and liver resection for noncolorectal liver metastases","volume":"183","author":"Goering","year":"2002","journal-title":"Am. J. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.euo.2018.06.007","article-title":"Systematic Review of the Management of Local Kidney Cancer Relapse","volume":"1","author":"Kriegmair","year":"2018","journal-title":"Eur. Urol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/02656736.2019.1647352","article-title":"Percutaneous ablation techniques for renal cell carcinoma: Current status and future trends","volume":"36","author":"Filippiadis","year":"2019","journal-title":"Int. J. Hyperth."},{"key":"ref_23","first-page":"537.e1","article-title":"Thermal ablation for small renal masses: Identifying the most appropriate tumor size cut-off for predicting perioperative and oncological outcomes","volume":"40","author":"Luzzago","year":"2022","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/02656736.2021.1923837","article-title":"Real-Time US-CT fusion imaging for guidance of thermal ablation in of renal tumors invisible or poorly visible with US: Results in 97 cases","volume":"38","author":"Mauri","year":"2021","journal-title":"Int. J. Hyperth."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/JU.0000000000001912","article-title":"Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II","volume":"206","author":"Campbell","year":"2021","journal-title":"J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/JU.0000000000001911","article-title":"Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I","volume":"206","author":"Campbell","year":"2021","journal-title":"J. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.juro.2016.04.081","article-title":"Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis","volume":"196","author":"Pierorazio","year":"2016","journal-title":"J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jvir.2017.12.020","article-title":"Thermal Ablation of T1c Renal Cell Carcinoma: A Comparative Assessment of Technical Performance, Procedural Outcome, and Safety of Microwave Ablation, Radiofrequency Ablation, and Cryoablation","volume":"29","author":"Zhou","year":"2018","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00345-018-2546-6","article-title":"Available ablation energies to treat cT1 renal cell cancer: Emerging technologies","volume":"37","author":"Zondervan","year":"2019","journal-title":"World J. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/02656736.2017.1408147","article-title":"Percutaneous microwave ablation of renal cell carcinoma using a high power microwave system: Focus upon safety and efficacy","volume":"34","author":"Filippiadis","year":"2018","journal-title":"Int. J. Hyperth."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1080\/02656736.2020.1778801","article-title":"Image-guided thermal ablation of central renal tumors with retrograde cold pyeloperfusion technique: A monocentric experience","volume":"37","author":"Mauri","year":"2020","journal-title":"Int. J. Hyperth."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Mauri, G., Mistretta, F.A., Bonomo, G., Camisassi, N., Conti, A., Della Vigna, P., Ferro, M., Luzzago, S., Maiettini, D., and Musi, G. (2020). Long-term follow-up outcomes after percutaneous us\/ct-guided radiofrequency ablation for ct1a-b renal masses: Experience from single high-volume referral center. Cancers, 12.","DOI":"10.3390\/cancers12051183"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s13244-017-0555-4","article-title":"Tips and tricks for a safe and effective image-guided percutaneous renal tumour ablation","volume":"8","author":"Mauri","year":"2017","journal-title":"Insights Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jvir.2012.03.002","article-title":"Percutaneous Cryoablation of Metastatic Renal Cell Carcinoma for Local Tumor Control: Feasibility, Outcomes, and Estimated Cost-effectiveness for Palliation","volume":"23","author":"Bang","year":"2012","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.juro.2014.03.006","article-title":"Feasibility and Oncologic Control after Percutaneous Image Guided Ablation of Metastatic Renal Cell Carcinoma","volume":"192","author":"Welch","year":"2014","journal-title":"J. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.juro.2009.01.043","article-title":"Predictors of Oncological Outcome After Resection of Locally Recurrent Renal Cell Carcinoma","volume":"181","author":"Margulis","year":"2009","journal-title":"J. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0022-5347(05)67350-8","article-title":"Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy","volume":"164","author":"Itano","year":"2000","journal-title":"J. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0022-5347(05)65167-1","article-title":"Outcome Of Surgical Treatment Of Isolated Local Recurrence After Radical Nephrectomy For Renal Cell Carcinoma","volume":"167","author":"Hakenberg","year":"2002","journal-title":"J. Urol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1477-2574.2012.00495.x","article-title":"A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer","volume":"14","author":"Hatzaras","year":"2012","journal-title":"HPB"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMe1806331","article-title":"Cytoreductive Nephrectomy\u2014Patient Selection Is Key","volume":"379","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jamaoncol.2018.5503","article-title":"Cytoreductive Nephrectomy in Metastatic Renal Cell Cancer","volume":"5","author":"Lara","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): Long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2022.09.020","article-title":"Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial","volume":"177","author":"Apolo","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","article-title":"Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update","volume":"94","author":"Choueiri","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Gonnet, A., Salabert, L., Roubaud, G., Catena, V., Brouste, V., Buy, X., Goupil, M.G., Ravaud, A., and Palussi\u00e8re, J. (2019). Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: Over 10 years of experience. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6345-2"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/15\/4902\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:19:06Z","timestamp":1760127546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/15\/4902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":50,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["jcm12154902"],"URL":"https:\/\/doi.org\/10.3390\/jcm12154902","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]}}}